Precision Begins With One

Prof. Dean Ho and his team pioneered the development of CURATE.AI, an AI-enabled platform that dynamically optimises human drug dosing for indications ranging from hematologic and solid cancers to cardiovascular medicine and digital therapy. CURATE.AI is currently being studied across multiple first-in-kind clinical trials which have led to promising clinical outcomes. Lessons learned from AI-driven, N-of-1 healthcare has also led to new studies pertaining to Digital Longevity Medicine to address the need to extend human healthspan.

In October of 2024, Prof. Dean Ho and team launched DELTA, a first-in-kind human trial – with Prof. Dean Ho as the test subject. This N-of-1 protocol harnesses a combination of AI, digital medicine, fasting, fitness, and food to optimize metabolic health, monitored using an array of digital health platforms. Built from an unprecedented dataset, this study will culminate in a digital twin of Dean to hyper-personalise his cardiometabolic health protocol. Outcomes from this trial will create data collection frameworks to power population-scale healthspan optimisation and design regimens that do not require sustained digital monitoring to impact even larger communities.